NAD+

NAD+ (also known as NAD+ or Nicotinamide Adenine Dinucleotide) is a therapeutically researched peptide studied for its effects on anti-aging, recovery, metabolic health. Essential cellular coenzyme for energy, DNA repair, and aging. Precursors (NMN/NR) or IV boost NAD+ levels. Cellular benefits proven, longevity unproven.

NAD+ (Nicotinamide Adenine Dinucleotide) is a critical coenzyme found in all living cells that plays essential roles in cellular metabolism, energy production, DNA repair, and aging processes. NAD+ levels naturally decline with age (up to 50% by middle age), contributing to mitochondrial dysfunction, reduced cellular repair capacity, and various age-related conditions. NAD+ serves as a crucial substrate for sirtuins (SIRT1-7) and poly(ADP-ribose) polymerase (PARP) enzymes that regulate cellular longevity, stress adaptation, and DNA repair mechanisms.

Overview

While NAD+ itself is poorly absorbed orally, precursor compounds including Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN) effectively increase NAD+ levels via salvage pathways.

Clinical trials demonstrate NR/NMN supplementation (250-1000mg daily) safely elevates blood NAD+ levels, with observed improvements in mitochondrial function, insulin sensitivity, muscle performance, and cardiovascular markers.

However, experts emphasize there is no conclusive evidence that NAD+ supplementation extends human lifespan despite cellular benefits.

Common administration methods include oral supplementation (NR/NMN), IV infusions (500-1500mg, 2-4 hours), and subcutaneous injections (50-100mg weekly).

Side effects are generally mild and transient, including nausea, flushing, headache, and GI discomfort.

Potential concerns include unknown long-term safety profile, theoretical tumorigenesis risk (unproven in humans), and significant cost ($1000+ for IV sessions).

NAD+ restoration represents a promising but still investigational approach to cellular regenerative medicine, requiring more robust long-term human clinical trials to establish definitive therapeutic applications and longevity benefits.

Mechanism of action

Boosts cellular energy production and DNA repair. Activates longevity enzymes. Improves metabolism and mitochondrial health. Cellular benefits proven, human longevity unproven.

Reported effects

Effects reported in the literature and from preclinical models include:

• Oral nicotinamide reduced the incidence of new squamous cell carcinomas and actinic keratoses during active treatment in high-risk patients with previous non-melanoma skin cancer, and topical nicotinamide consistently improved wrinkles, texture irregularities, pigmentation, and skin barrier function. ^[5] Phase II
• A review of human supplementation studies found NAD+ precursors showed potential but inconsistent benefits for mitochondrial efficiency, cellular stress responses, and cognitive performance in older adults, with results varying across populations and dosing strategies. ^[4] Anecdotal
• Nicotinamide and NAD+ enhanced mitochondrial function and cognitive resilience in preclinical Alzheimer's models by countering PARP1-driven NAD+ and ATP depletion. ^[1] Preclinical
• Nicotinamide protected retinal ganglion cells in preclinical glaucoma work by supporting NAD levels and cellular bioenergetics. ^[6] Preclinical
• The NAD+/SIRT1 axis links energy metabolism to epigenetic and circadian regulation in the liver, and NAD+ restoration remains an experimental, mostly preclinical strategy for liver aging. ^[2] Preclinical
• NAD+ decline and dysregulated NAD+-dependent enzyme activity are implicated as drivers of mitochondrial dysfunction and cellular senescence in chronic kidney disease, inflammatory bowel disease, rheumatic disease, myocardial hypertrophy, lung disease, and general ageing, so NAD+ restoration is proposed as an experimental gerotherapeutic target. ^{[7][3][11][12][13][8][9][10]} Preclinical

Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal

Dosage and administration

Oral NMN

• Beginner: 250mg daily on empty stomach
• Intermediate: 500-600mg daily, split into 2 doses
• Advanced: 900-1200mg daily for intensive protocols

Oral NR

• Beginner: 100-300mg daily
• Standard: 500mg daily (most studied dose)
• Advanced: 1000-2000mg daily for therapeutic goals

IV Infusion

• Standard: 500-750mg per session over 2-4 hours
• Intensive: 1000-1500mg per session

Subcutaneous Injection

• Start: 50mg (0.5mL) once weekly for 4 weeks
• Maintenance: 100mg (1mL) 1-3x weekly

Timing

• Take oral forms morning/early afternoon (may affect sleep if taken late)

Frequency

• Oral daily, IV weekly to monthly, injections 1-3x weekly

Natty status

NAD+ is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.^[14]

Research

The peptide has been the subject of 51 studies and reference works collected on this site. Additional bibliography is in § External links below.

Related compounds

Other peptides in this catalogue with overlapping mechanisms or status:

References

1. ^ From DNA repair to neurodegeneration: PARP1 mechanisms and inhibitor strategies in Alzheimer's disease. Recent review
2. ^ Epigenetic Information Loss and Chronosenescence in Liver Aging: From Molecular Mechanisms to Therapeutic Interventions. Recent review
3. ^ Nicotinamide N-methyltransferase in Inflammatory bowel disease: Multidimensional Regulation, Mechanistic Insights, and Therapeutic Potential. Recent review
4. ^ Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits. Recent review
5. ^ Skin Cancer Prevention and Antiaging: Role of Nicotinamide. Recent review
6. ^ Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies. Recent review
7. ^ Nicotinamide N-methyltransferase as a stress-responsive metabolic-epigenetic regulator of tubular senescence in chronic kidney disease. Recent review
8. ^ Mitochondrial quality control in human ageing and longevity. Recent review
9. ^ Network Destabilization in Aging: Mitochondrial Dysfunction, Nutrient Sensing, and Chronic Inflammation as Interconnected Drivers. Recent review
10. ^ The mitochondrial logic of inflammaging: how energy imbalance drives fibroblast SASP and tissue-specific aging. Recent review
11. ^ SIRT1 as a Key Regulator in Rheumatic Diseases: Integrating Molecular Insights with Traditional Chinese Medicine Approaches. Recent review
12. ^ Research progress on metabolic abnormalities in myocardial hypertrophy. Recent review
13. ^ Advances in sirtuin research in lung diseases (Review). Recent review
14. ^ a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

• Wikipedia article
• Role of NAD+ in regenerative medicine
• Central role in aging prevention
• NMN safety and efficacy in healthy adults
• Chronic NR supplementation in older adults
• NR-SAFE high dose safety trial in Parkinson's
• NAD+ repletion improves mitochondrial function
• Insights into SIRT2 inhibition from machine learning-assisted multi-level screening of the NCI database.
• H(2)-dependent reduction of rubredoxin by FrhAGB hydrogenase in Thermococcus onnurineus NA1.
• Repurposing Syrosingopine for Cancer Therapy: Lactate Trapping and ISR Sensitization as Metabolic Vulnerabilities.
• Clinical and biochemical footprints of inherited cofactor disorders.
• Cofactor Engineering Strategy of Food-Grade Microorganisms: Redox Homeostasis Regulation and Functional Components Biofortification.
• From autophagy-lysosomal deficits to neurodegeneration in Niemann-Pick type C1 disease: implications for age-related neurodegenerative disorders.
• MicroRNA-SIRT1 crosstalk in liver diseases: molecular regulation of metabolism, inflammation, and cell survival.
• Nutritional Regulation of Ovarian Bioenergetics: Implications for Reproductive Aging and Female Infertility.
• The SIRT1/STAT3 axis as a central regulator of immune, inflammatory, and lipid metabolic dysregulation in rheumatoid arthritis: therapeutic implications.
• Mesenchymal Stromal Cell-Derived Extracellular Vesicles Mediate Mitochondrial Delivery in Injury: Mechanistic Insights, Evidentiary Tiers, and Translational Challenges.
• Metabolic reprogramming of myeloid cells in cancer: from lactate-NAMPT axis to AI-guided therapeutics.
• The myofascial rheostat: hyaluronan molecular weight dynamics and purinergic signalling as a physiological feedback system.
• Acetylation as a dynamic regulatory interface between plant stress memory, cross-tolerance, and crop resilience design.
• Cell-Type-Specific Calibration of Mitochondrial Ubiquitination in Stem Cell Fate Decisions.
• Mitochondrial dysfunction and cellular senescence drive accelerated gestational aging in spontaneous preterm birth: a narrative review.
• SIRT5/7 desuccinylation in cancer: linking metabolism, immunity, and drug resistance.
• Factors Determining Sirtuin-1 Target Engagement.
• Navigating the Metabolic-Genomic Paradigm: Mitochondrial Reprogramming as a Driver of Cancer Plasticity.
• Metabolic control of renal cell fate in kidney disease: nutrient rewiring, senescence and fibrosis.
• Decoding Context-Dependent Sirtuin Pharmacology in Cancer: Metabolic-Epigenetic Switches and Precision Therapeutic Targeting.
• Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways.
• Boron as a Context-Dependent System-Level Modulator: Mechanisms and Implications in Chronic Diseases.
• Metabolic therapeutic targets in Alzheimer's disease.
• Bidirectional regulation between mitochondrial metabolic reprogramming and epigenetic modifications in renal tubular epithelial cell injury of diabetic kidney disease.
• Deciphering the role of sirtuins in cancer immunoregulation through molecular cross-talk and docking-based interaction.
• NAD(+) supplementation and PARP inhibition following spinal cord injury in mice: Hurdles and considerations for therapeutic use.
• The organellar biology of aging: A mitochondrial vantage.
• Oxidative stress-driven epigenetic reprogramming of immune cells in COPD: from epitranscriptomic and metabolic crosstalk to treatable traits.
• [NAD kinases (NADKs) family proteins: Advances in metabolic regulation mechanisms and disease associations].
• Suppress, Stimulate, or Steer: Dioxygen Activation by Flavoenzymes and Their Oxygenation Strategies.
• Molecular mechanisms of traditional Chinese medicine in skin aging: a narrative review.
• 500mg NAD+ — commercial
• NAD+ + Spray Kit — commercial
• Bacteriostatic Water Reconstitution Solution 10ml — commercial